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JPPT
Case Report
Cinacalcet Administration by Gastrostomy Tube in a Child Receiving
Peritoneal Dialysis
Kristen R. Nichols, PharmD,1,2 Chad A. Knoderer, PharmD,1 Bethanne Johnston, MSN,3 and Amy C. Wilson, MD3
Department of Pharmacy Practice, College of Pharmacy and Health Sciences, Butler University, Indianapolis,
Indiana, 2Department of Pharmacy, Riley Hospital for Children, Indiana University Health, Indianapolis, Indiana,
3
Department of Pediatrics, Section of Pediatric Nephrology, Indiana University School of Medicine, Indianapolis,
Indiana
1

A 2-year-old male with chronic kidney disease with secondary hyperparathyroidism developed hypercalcemia while receiving calcitriol, without achieving a serum parathyroid hormone concentration within the
goal range. Cinacalcet 15 mg (1.2 mg/kg), crushed and administered via gastrostomy tube, was added to
the patient’s therapy. This therapy was effective in achieving targeted laboratory parameters in our patient
despite instructions in the prescribing information that cinacalcet should always be taken whole.
INDEX TERMS: chronic kidney disease, cinacalcet, hypercalcemia, secondary hyperparathyroidism
J Pediatr Pharmacol Ther 2014;19(3):202–205

INTRODUCTION

CASE REPORT

Abnormal bone and mineral metabolism and
secondary hyperparathyroidism are well-described consequences of chronic kidney disease
(CKD), with progression to renal osteodystrophy,
growth impairment, and vascular calcification if
left untreated. Overcorrection is associated with
adynamic bone disease.1 In addition to dietary
phosphate binders, active vitamin D sterols
are recommended to prevent bone disorders.
Calcitriol (Rocaltrol, Roche Pharmaceuticals,
Nutley, NJ) is the most commonly used form of
vitamin D replacement in children who require
renal replacement therapy, though its use can
be limited by hypercalcemia.2 Alternatives associated with lower risk for hypercalcemia are
available for adults, including doxercalciferol
(Hectorol, Genzyme Corporation, Cambridge,
MA), paricalcitol (Zemplar, Abbvie Inc, North
Chicago, IL), and cinacalcet (Sensipar, Amgen,
Thousand Oaks, CA), but optimal dosage regimens in children receiving peritoneal dialysis
(PD) are lacking.3 We aim to describe our use of
an alternate administration method for cinacalcet
in a child with CKD, hypercalcemia, and secondary hyperparathyroidism.

A 2-year-old, 10.3-kg, Caucasian male with a
history of CKD presented to the pediatric clinic
for evaluation for peritoneal dialysis after an
emergency department admission for worsening
vomiting and dehydration and was found to have
stage 5 CKD. His past medical history was significant for bilateral renal dysplasia, vesicoureteral
reflux, posterior urethral valves, chronic vomiting with failure to thrive, and CKD with anemia
and secondary hyperparathyroidism.
At that time, he was receiving calcitriol 0.2
mcg (0.02 mcg/kg) per gastrostomy tube (GT)
twice daily and cinacalcet 6 mg (0.6 mg/kg) by
GT. The 30-mg cinacalcet tablet (Sensipar) was
crushed and mixed with 10 mL of water. A 5-mL
portion of the solution was then administered
for treatment of secondary hyperparathyroidism. The cinacalcet product was prepared fresh
each time it was administered and the remainder
of the water/cinacalcet mixture was discarded.
He was also receiving sodium and potassium
phosphorous (2-mmoL phosphorus = ¼ packet
250 mg twice daily), but adherence to this regimen was uncertain.
Laboratory results on this regimen were as
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Table. Patient Information and Laboratory Parameters
Patient information
Height, cm
Weight, kg
Medication

Laboratory value
(institution normal for age)
PTH, pg/mL (10-65 pg/mL)*
Phosphorus, mg/dL (3.5-6.5 mg/dL)
Calcium, mg/dL (8.5-10.5 mg/dL)
Albumin, g/dL (3.1-4.7 g/dL)
Serum creatine, mg/dL (0.2-0.7 mg/dL)

Presentation

+ 3 Months

+ 5 Months

+ 6 Months

76.5
10.3
Calcitriol
0.2 mcg BID
Cinacalcet
6 mg (adherence
uncertain)

80
12.4
Calcitriol
0.2 mcg

12.7
Calcitriol
0.15 mcg

84.5
13.9
Calcitriol
0.15 mcg
Cinacalcet 15 mg

596
3.3
11
3.9
3.61

368
6.1
11
3.3
5.11

513
3.5
10
3.2
4.49

246
5.2
9.6
3.1
3.57

BID, twice daily; ESRD, end-stage renal disease; PTH, parathyroid hormone
* ESRD goal, 200- 300 pg/mL

follows (see Table): serum calcium 11 mg/dL
(normal, 8.5-10.5 mg/dL), phosphorus 3.3 mg/
dL (normal, 3.5-6.5 mg/dL), and parathyroid
hormone (PTH) 596 pg/mL (goal, 200-300 pg/
mL). In an attempt to improve his management
and simplify his medication regimen, cinacalcet was discontinued and calcitriol (Rocaltrol)
was changed to a dose of 0.2 mcg (0.02 mcg/kg
once daily. In addition, his enteral formula was
changed from Similac PM 60/40 to half Similac
Advance (Abbott, Abbott Park, IL) with half Similac PM 60/40 (Abbott) to increase the amount of
phosphorous supplementation. At that time, both
his weight and length were lower than the third
percentile for his age.
At a 3-month follow-up visit, his serum calcium
concentration remained elevated at 11 mg/dL. At
this time his phosphorus concentration was within the normal range at 6.1 mg/dL but his PTH
concentration remained elevated at 368 pg/mL.
Calcitriol was decreased to 0.15 mcg (0.012 mcg/
kg) per GT once daily. Two months following the
calcitriol dose reduction, the calcium concentration had normalized (10 mg/dL); unfortunately,
the PTH concentration remained elevated (513
pg/mL). Phosphorous concentration remained
in the low-normal range throughout this period
(3.5 mg/dL). The patient was subsequently given
15 mg (approximately 1.2 mg/kg) of cinacalcet
extemporaneously as prepared above.
One month following the addition of cinacalcet
the PTH concentration was within the goal range
of 200 to 300 pg/mL, at 246 pg/mL, as were his
J Pediatr Pharmacol Ther 2014 Vol. 19 No. 3 • www.jppt.org

calcium (9.6 mg/dL) and phosphorus (5.2 mg/
dL) concentrations. He subsequently required an
increase in the dose of calcitriol to 0.2 mcg (0.015
mcg/kg) owing to increasing PTH concentrations. By this time the patient had demonstrated
improvement in his growth, with a weight of
13.2 kg.

DISCUSSION
Active vitamin D therapy, namely with calcitriol, is recommended by the KDOQI (Kidney
Disease Outcomes Quality Initiative) Clinical
Practice Guidelines for Bone Metabolism and
Disease in Children with Chronic Kidney Disease
for children with PTH serum concentrations that
are above the target range for CKD stage.1 Our
patient likely experienced calcitriol-associated
hypercalcemia due to the increased gastrointestinal tract absorption of calcium and phosphorus.2 The KDOQI guidelines recommend that
for serum calcium concentrations greater than
10.2 mg/dL, the calcitriol should be held until
the serum calcium concentration is less than 9.8
mg/dL and restarted at half of the previous dose.
Unfortunately, this may not result in a serum PTH
concentration within the goal range.1
For adults with CKD and secondary hyperparathyroidism, alternative options are available
for active vitamin D therapy and PTH suppression. The vitamin D analogs paracalcitol and doxercalciferol have a lesser effect on the absorption
of calcium in the gastrointestinal tract but still
203

JPPT
reduce serum PTH concentrations.3–5 These are
not available in formulations for patients who
are unable to swallow a solid dosage form (as
with our patient). Both alternatives are available
as soft gelatin capsules, and though the contents
can be evacuated with a syringe for subsequent
administration, this strategy may be difficult and
inexact.6,7 This technique does not allow lesser
amounts than available dosage forms to be easily
administered. While both paracalcitol and doxercalciferol are available as intravenous formulations, parenteral administration is not practical
for PD patients, who are typically seen in clinic
only 1 to 2 times per month.6,7 No information
was found to support the use of the intravenous
formulations enterally, though this could be an
alternative option to investigate.
Though vitamin D therapy (calcitriol) has
been shown to be effective in suppressing hyperthyroidism in end-state renal disease (ESRD)
patients, resulting hypercalcemia is undesirable
owing to potential for adverse effects and cardiovascular disease.8 Cinacalcet is a calcimimetic
that increases the sensitivity of the calcium-sensing receptor on the parathyroid gland, leading
to a decreased PTH concentration without a
concomitant increase in serum calcium.3 It also
increases the expression of vitamin D receptors
on the thyroid gland, potentially allowing for a
lower effective calcitriol dose.8 Cinacalcet has
been studied in a small number of children and
adolescents with ESRD and has been shown to
result in decreased PTH without elevation in
calcium or phosphorus.9–11 These studies have
added cinacalcet to calcitriol therapy. Therefore,
cinacalcet may be an additive option in children
and adolescents with ESRD when the dose of
calcitriol is limited by hypercalcemia (serum calcium >10.2 mg/dL) and the PTH concentration
is above the goal range. Combination therapy
may also result in a decrease in phosphate binder
requirement.10 The dose used in our patient was
chosen from a review of the experience as published by Platt and colleagues,9 where a wide
initial dosing range of 0.4 to 1.4 mg/kg was used,
and for simplicity of preparation by the patient’s
caregiver.
Calcium should be closely monitored during
therapy, and consideration for cinacalcet discontinuation or dose reduction should be given
if the serum calcium concentration decreases to
less than 8.4 mg/dL. Though used for only a
204
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short time period in these studies, cinacalcet has
been generally well tolerated until the report of
the recent death of a 14-year-old adolescent during a cinacalcet clinical trial.12 The US Food and
Drug Administration stopped all pediatric clinical trials of cinacalcet and issued a drug safety
communication until the cause of the death can
be determined; causality has not been assigned.12
Liquid dosage forms of cinacalcet are not
available. To administer 15 mg (approximately
1.2 mg/kg), we instructed the parents to crush
a 30-mg tablet, mix it with 10 mL of water, and
administer 5 mL. The tablet was not to be halved
before crushing, as it is not scored. Prescribing
information indicates that the available tablet
dosage form should be swallowed whole and
not divided, though there is no evidence to
demonstrate that crushing the tablet would result
in drug inactivation. Administration of weightbased cinacalcet to a group of 7 pediatric patients
was described by Muscheites and colleagues,10
whereby 30-mg tablets were ground into powder
and re-pressed into tablets containing 2.5, 5, and
7.5 mg. The resultant diminished serum PTH,
phosphorus, and calcium concentrations were
reassuring and indicated that cinacalcet could be
safely crushed for administration in our patient.
An additional study that evaluated single-dose
cinacalcet in pediatric patients used a 15-mg
dose, achieved by splitting a 30-mg tablet.13 The
split tablet was weighed to confirm the appropriate dose and administered with 90 ml of water;
unfortunately, it is not clear in this study whether
the split tablet was subsequently crushed or was
swallowed whole.
We believe that the GT administration of cinacalcet after crushing has no deleterious results on
the medication’s effectiveness. This is supported
by the normalization of our patient’s laboratory
parameters (serum PTH and calcium within goal
range). The normalization was temporally associated with cinacalcet administration via GT in
the absence of other interventions. More data are
needed to determine the role of cinacalcet therapy
in children with CKD and if GT administration
results in outcomes similar to administration of
the solid tablet form. Our experience with this
case supports the use of cinacalcet when crushed
for GT administration.
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